SCHEMBL1243522

SCHEMBL1243522

Cc1cc(C)cc(NC2=C(Cl)C(=O)c3ccccc3C2=O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.73
▸ RAB9A P51151 10/20 0.73
▸ HTT P42858 10/20 0.73
▸ KMT2A Q03164 9/20 0.73
▸ MEN1 O00255 7/20 0.73
▸ NPC1 O15118 7/20 0.73
▸ MITF O75030 3/20 0.73
▸ NPSR1 Q6W5P4 8/20 0.67
▸ MAPK1 P28482 7/20 0.67
▸ ATM Q13315 5/20 0.67
▸ LMNA P02545 4/20 0.67
▸ GAA P10253 3/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ XBP1 P17861 1/20 0.67
▸ ALDH1A1 P00352 6/20 0.59
▸ L3MBTL1 Q9Y468 4/20 0.59
▸ TDP1 Q9NUW8 4/20 0.59
▸ HPGD P15428 3/20 0.59
▸ NSD2 O96028 2/20 0.59
▸ TP53 P04637 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868219 0.85 MAPT (1.00) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL6506683 0.80 MAPT (1.00) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL29633261 0.80 MAPT (1.00) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL15906855 0.80 MAPT (0.60) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL1242311 0.80 MAPT (0.67) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL7240445 0.78 MAPT (0.74) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL5808588 0.78 MAPT (0.68) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL32664539 0.77 MAPT (0.79) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL15906857 0.77 MAPT (0.64) MAPTRAB9AHTTKMT2AMEN1
SCHEMBL12283300 0.77 MAPT (0.58) MAPTRAB9AHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 — — US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 — — US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAPT 1551/4885RAB9A 1980/4885HTT 784/4885
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders METAP1, METAP2, ENPEP MAPT 1551/4885RAB9A 1980/4885HTT 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback